Drug Profile
Vicriviroc/MK 2048
Alternative Names: MK 2048/MK 4176; MK 2048/vicriviroc; MK 2048A IVR; MK 4176/MK 2048; VCV/MK 2048Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Class Naphthyridines; Piperazines; Pyrimidines; Pyrimidinones
- Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Vaginal, Ring)
- 17 Jul 2015 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for HIV infections (Prevention, In volunteers) in USA (NCT02419456)
- 18 Jun 2015 Phase-I clinical trials in HIV infections (Prevention, In volunteers) in USA (Vaginal) (NCT02356302)